Mankind Pharma Acquires Remaining Stake in Upakarma Ayurveda, Achieving Full Ownership
Mankind Pharma Limited has completed the acquisition of the remaining 10% stake in Upakarma Ayurveda Private Limited. The deal was finalized through a Share Purchase Agreement (SPA) dated June 2, 2026, marking a significant step toward consolidating Upakarma's operational structure within the company's subsidiaries.The acquisition was executed by Mankind Lifesciences Private Limited (MLS), a wholly-owned subsidiary of Mankind Pharma Limited, from Kaushcorp Media LLP. Following this transaction, Upakarma Ayurveda Private Limited has become a wholly-owned subsidiary of MLS and consequently, a step-down subsidiary of Mankind Pharma Limited.
The purpose of the acquisition is stated to enable the Company to achieve better operational efficiencies through streamlined processes.
Upakarma Ayurveda Profile and Transaction Details
Upakarma Ayurveda Private Limited, a company engaged in the ayurvedic, herbal, and nutraceutical products sector, was incorporated on November 28, 2017. The entity was previously noted as becoming a step-down subsidiary of the Company on November 9, 2022.The acquisition involved a cash consideration of ₹ 75 Lakhs for the remaining 10% stake in Upakarma. After the successful completion of this purchase, MLS now holds a 100% stake in Upakarma, confirming its consolidated ownership.
For a detailed overview of Upakarma and the transaction, the following figures were provided:
| Metric | Detail |
|---|---|
| Target Entity | Upakarma Ayurveda Private Limited |
| Industry | Ayurvedic, herbal and nutraceutical products |
| Authorized Share Capital | ₹ 2.00 Crores |
| Paid-up Share Capital | ₹ 1.80 Crores |
| Turnover (as on March 31, 2026) | ₹ 18.02 Crores |
| Acquisition Cost | ₹ 75 Lakhs |
| Consideration Form | Cash Consideration |
| Stake Acquired | Remaining 10% stake |
| Total Stake Held by MLS | 100% |
| Geographic Presence | India |
MANKIND Stock Price Movement
Mankind Pharma Limited shares today slipped by 1.11% to settle at ₹2299, dropping ₹25.80 in after-hours trading. The stock traded on a volume of 777,828 shares, reflecting noticeable selling pressure throughout the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.